Understanding how antibodies from peanut oral immunotherapy protect against allergies
Structural and functional characterization of protective antibodies induced in peanut oral immunotherapy
This study is looking at how certain antibodies created during peanut treatment can help keep you safe from peanut allergies in the long run, and by joining in, you could help us learn more about how to make food allergies easier to manage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10994621 on NIH RePORTER |
What this research studies
This research investigates the role of specific antibodies generated during peanut oral immunotherapy (OIT) in providing long-term protection against peanut allergies. By analyzing how these antibodies suppress allergic reactions at a cellular level, the study aims to uncover the mechanisms that lead to clinical tolerance in patients. The approach involves examining the interaction between peanut-specific IgG antibodies and immune cells, which could lead to new antibody-based treatments for food allergies. Patients participating in this research may contribute to a better understanding of how to achieve lasting allergy relief.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a diagnosed peanut allergy who are undergoing or have undergone oral immunotherapy.
Not a fit: Patients with allergies to foods other than peanuts or those who do not have a history of peanut allergies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for peanut allergies, potentially allowing patients to tolerate peanuts without severe allergic reactions.
How similar studies have performed: Previous research has shown promising results in understanding the role of antibodies in food allergy tolerance, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Patil, Sarita U — Massachusetts General Hospital
- Study coordinator: Patil, Sarita U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.